FY2026 EPS Estimates for McKesson Raised by Zacks Research

McKesson Corporation (NYSE:MCK - Free Report) - Equities researchers at Zacks Research increased their FY2026 earnings per share (EPS) estimates for shares of McKesson in a note issued to investors on Tuesday, June 17th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $36.87 per share for the year, up from their previous estimate of $36.77. The consensus estimate for McKesson's current full-year earnings is $32.77 per share. Zacks Research also issued estimates for McKesson's Q4 2026 earnings at $10.52 EPS, Q1 2027 earnings at $9.96 EPS, Q2 2027 earnings at $9.63 EPS, FY2027 earnings at $41.61 EPS and FY2028 earnings at $46.38 EPS.

Other equities research analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of McKesson from a "strong-buy" rating to a "buy" rating in a research report on Saturday, June 14th. Mizuho lifted their price target on shares of McKesson from $630.00 to $690.00 and gave the stock a "neutral" rating in a research note on Thursday, April 3rd. Morgan Stanley upped their price objective on shares of McKesson from $745.00 to $770.00 and gave the company an "overweight" rating in a research note on Wednesday, June 11th. Bank of America boosted their target price on McKesson from $755.00 to $800.00 and gave the company a "buy" rating in a report on Friday, May 9th. Finally, Cfra Research lowered McKesson from a "moderate buy" rating to a "hold" rating in a research report on Friday, April 4th. Three equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $694.38.

McKesson Price Performance

MCK stock opened at $729.28 on Thursday. The business's 50-day moving average is $706.79 and its two-hundred day moving average is $646.38. The firm has a market capitalization of $91.24 billion, a P/E ratio of 28.23, a P/E/G ratio of 1.44 and a beta of 0.49. McKesson has a 1 year low of $464.42 and a 1 year high of $732.99.

McKesson (NYSE:MCK - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $10.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $9.83 by $0.29. McKesson had a net margin of 0.92% and a negative return on equity of 201.12%. The company had revenue of $90.82 billion for the quarter, compared to analyst estimates of $94 billion. During the same period in the prior year, the firm earned $6.18 earnings per share. The business's revenue for the quarter was up 18.9% compared to the same quarter last year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 1st. Investors of record on Monday, June 2nd will be paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date of this dividend is Monday, June 2nd. McKesson's payout ratio is currently 10.99%.

Insider Transactions at McKesson

In other McKesson news, CFO Britt J. Vitalone sold 6,336 shares of the firm's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $717.30, for a total value of $4,544,812.80. Following the sale, the chief financial officer now directly owns 14,760 shares of the company's stock, valued at approximately $10,587,348. This trade represents a 30.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Brian S. Tyler sold 19,370 shares of McKesson stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $705.93, for a total value of $13,673,864.10. Following the completion of the sale, the chief executive officer now owns 51,243 shares of the company's stock, valued at $36,173,970.99. This trade represents a 27.43% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,117 shares of company stock valued at $23,526,451 over the last three months. 0.11% of the stock is currently owned by insiders.

Hedge Funds Weigh In On McKesson

A number of hedge funds have recently made changes to their positions in MCK. CVA Family Office LLC grew its position in McKesson by 6.0% during the 1st quarter. CVA Family Office LLC now owns 265 shares of the company's stock worth $178,000 after acquiring an additional 15 shares during the last quarter. Palisade Asset Management LLC boosted its holdings in McKesson by 2.1% during the first quarter. Palisade Asset Management LLC now owns 715 shares of the company's stock worth $481,000 after buying an additional 15 shares during the last quarter. SteelPeak Wealth LLC raised its holdings in McKesson by 0.5% in the first quarter. SteelPeak Wealth LLC now owns 2,771 shares of the company's stock worth $1,867,000 after purchasing an additional 15 shares during the period. Parallel Advisors LLC grew its stake in McKesson by 0.6% in the first quarter. Parallel Advisors LLC now owns 2,501 shares of the company's stock valued at $1,683,000 after acquiring an additional 16 shares during the period. Finally, Frank Rimerman Advisors LLC increased its holdings in shares of McKesson by 2.2% in the fourth quarter. Frank Rimerman Advisors LLC now owns 807 shares of the company's stock worth $460,000 after acquiring an additional 17 shares in the last quarter. Institutional investors and hedge funds own 85.07% of the company's stock.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.